96
Participants
Start Date
October 28, 2019
Primary Completion Date
May 7, 2021
Study Completion Date
May 7, 2021
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)
6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Trivalent Invasive Salmonella Disease Vaccine (12 µg)
12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Trivalent Invasive Salmonella Disease Vaccine (25 µg)
25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)
The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
Placebo
0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore
University of Maryland, Baltimore
OTHER